VNRX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
VNRX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.
VolitionRX's Capital Expenditure for the three months ended in Mar. 2024 was $-0.08 Mil. Its Cash Flow from Operations for the three months ended in Mar. 2024 was $-8.34 Mil.
GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.
The historical data trend for VolitionRX's Capex-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VolitionRX Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Capex-to-Operating-Cash-Flow | Get a 7-Day Free Trial | - | - | - | - | - |
VolitionRX Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Capex-to-Operating-Cash-Flow | Get a 7-Day Free Trial | - | - | - | 0.05 | - |
For the Diagnostics & Research subindustry, VolitionRX's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Diagnostics & Research industry and Healthcare sector, VolitionRX's Capex-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where VolitionRX's Capex-to-Operating-Cash-Flow falls into.
VolitionRX's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2023 is calculated as
Capex-to-Operating-Cash-Flow | = | - Capital Expenditure | / | Cash Flow from Operations |
= | - (-1.084) | / | -18.063 | |
= | N/A |
VolitionRX's Capex-to-Operating-Cash-Flow for the quarter that ended in Mar. 2024 is calculated as
Capex-to-Operating-Cash-Flow | = | - Capital Expenditure | / | Cash Flow from Operations |
= | - (-0.079) | / | -8.342 | |
= | N/A |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VolitionRX (AMEX:VNRX) Capex-to-Operating-Cash-Flow Explanation
Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.
Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.
Thank you for viewing the detailed overview of VolitionRX's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Eight Corp Ltd | 10 percent owner | C/O CROWE MORGAN, 8 ST. GEORGE'S STREET, DOUGLAS Y8 IM1 1AH |
Salvatore Thomas Butera | director | 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014 |
Rodney Gerard Rootsaert | director, officer: SECRETARY | 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014 |
Cameron John Reynolds | director, officer: PRESIDENT AND CEO | 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014 |
Guy Archibald Innes | director | 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014 |
Edward Futcher | director | 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014 |
Phillip Barnes | director | 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014 |
Martin Charles Faulkes | director | 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014 |
Mickie Henshall | director | 1489 WEST WARM SPRINGS ROAD,, SUITE 110, HENDERSON NV 89014 |
Jacob Vincent Micallef | officer: Chief Scientific Officer | 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014 |
Michel Gaetan | other: Manager Belgian Volition SPRL | 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014 |
Jasmine Kway | other: CEO-Singapore Volition | 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014 |
Nicholas Plummer | officer: GC - Volition Diagnostics | 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014 |
Ann-louise Batchelor | officer: Group Chief Marketing Officer | 1489 WEST WARM SPRINGS ROAD,, SUITE 110, HENDERSON NV 89014 |
Terrell Jason Bradley Md | officer: Chief Medical Officer | 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014 |
From GuruFocus
By PRNewswire PRNewswire • 01-20-2023
By PRNewswire PRNewswire • 11-14-2022
By PRNewswire • 10-19-2023
By PRNewswire PRNewswire • 05-05-2023
By PRNewswire • 10-02-2023
By PRNewswire • 11-14-2023
By PRNewswire PRNewswire • 06-01-2023
By PRNewswire PRNewswire • 02-16-2023
By PRNewswire • 12-05-2023
By PRNewswire • 10-18-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.